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INTRODUCTION
China is a multiple ethnic country comprising 56 ethnic 
groups. As the majority of the population belongs to the Han 
ethnic group, China’s other 55 ethnic groups are customarily 
referred to as the national minorities. Xinjiang is the largest 
administrative region located in the northwest of China, span-
ning over 1.6 million km2. It is home to a number of different 
ethnic groups including the Han, Uyghur, Kazakh, Hui, Kyrgyz, 
Mongol, etc. Three of the groups had a population of more 
than one million, including Han (8.75 million), Uyghur (8.8 
million), and Kzakh (1.35 million) [1]. To date, only a few 
studies have been reported on BRCA-associated breast cancer 
in China; they included families with early-onset breast (under 
the age of 35 years) patients or with family history of breast/
ovarian cancer or bilateral breast cancer [2-4]. These studies 
revealed some characteristics of BRCA-related cancer in 
Chinese: the prevalence in Chinese population was lower than 
those in Caucasian and other Asian patients. On the other 
hand, no characteristic mutation spots were reported in main-
land China. All the above mentioned studies only involved 
ethnic Han Chinese. Up to now, few studies have investigated 
the prevalence of BRCA1 and BRCA2 germline mutation 
among patients in the multiple ethnic regions of China. We 
believe it is of great significance to have an overview of these 
two genes among the Chinese high-risk breast cancer patients 
in multiple ethnic regions of China, so as to develop genetic 
screening guidelines for the Chinese women.
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Purpose: The aim of this study is to further understand the status 
of BRCA1 and BRCA2 mutation among Chinese high-risk breast 
cancer patients in multiple-ethnic regions of China. Methods: A 
total of 79 blood samples of high-risk breast cancer patients 
from Xinjiang Uyghur autonomous region were analyzed by 
PCR-DHPLC sequencing analysis. Results: Analysis with full 
length of the two genes identified a total of 6 deleterious muta-
tions (2073delA, 2394C-T [Q759X] and IVS16+1G>A in BRCA1; 
1627A-T [K467X], 6873delCTCC and 9481delA in BRCA2) in 
this cohort. The prevalence of BRCA1/2 germline mutation was 
about 7.6% (6/79) in the Xinjiang multiple ethnic region of China. 
Among them, 3 novel deleterious mutations, 2073delA in BRCA1 
(Han ethnic Chinese) and BRCA2 variants 6873delCTCC and 
9481delA (both are Kazakh ethnic Chinese), were identified and 
they had never been reported in breast cancer information core 
(BIC) database before. 2394C-T (Q759X) and IVS16+1G>A, in 
BRCA1 and BRCA2 variants 1627A-T were previously reported 
in other populations but not Chinese. Among 6 of the BRCA-
related tumors, three BRCA1- and one BRCA2-associated tumors 
were in triple negative (estrogen receptor, progesterone receptor, 
and HER2 negative expressed) status and exhibited a high tumor 
grade. So far none of these 6 deleterious mutations were reported 
in ethnic Han Chinese. Conclusion: BRCA germline mutation in 
Chinese multiple ethnicity region may exhibit different genotypes 
compared to ethnic Han Chinese in other regions. These differenc-
es may arise from interaction of genetic background and environ-
mental factors.
Key Words: BRCA1, BRCA2, Breast neoplasms, Chinese, Ethnic groups, 
Genetic variation 
Correspondence to: Halmurat Upur
Xinjiang Medical University, 393 Xinyi Road, Urumqi 830011, China 
Tel: +86-22-2721-9052, Fax: +86-22-2721-9052 
E-mail: neuroman@163.com
This research was supported by National Natural Science Foundation of 
China (Grant number: 30960435).
Received: October 16, 2012 Accepted: December 26, 2012
Journal of        Breast
Cancer




All patient cases were recruited from the Xinjiang Cancer 
Institute and Hospital of Xinjiang Medical University, Xinjiang, 
China. The patients were included if one of the following items 
was met: 1) at least one first or second degree relative with 
breast cancer and/or ovarian cancer, regardless of age; 2) at 
least one first-degree relative with malignant tumors other 
than breast cancer and ovarian cancer; 3) breast cancer onset 
age below 35 years; 4) bi-lateral breast cancer; or 5) triple nega-
tive breast cancer (estrogen receptor [ER], progesterone re-
ceptor [PR], and HER2/neu negative) with onset age below 45 
years of age. Seventy-nine breast cancer patients, who received 
the standard treatment at the Xinjiang Cancer Institute and 
Hospital during 2005 to 2011, were finally included. Their 
family histories were retrieved from the medical records and 
ascertained by the families and/or patients in person with 
standard questionnaires procedure. All the cases were from 
different families. The study was approved by the Ethics Com-
mittee (IRB approval number: XJYD1320) of the Cancer Hos-
pital of Xinjiang Medical University and informed consents 
were obtained from all participants.
Mutation analysis 
Genomic DNA was isolated from 5 mL peripheral blood and 
stored in 10 mM Tris (pH 8) EDTA at 4°C. Specific BRCA1 and 
BRCA2 coding regions and intron-exon boundaries, ranging 
from 206 to 639 bp in length, were amplified by polymerase 
chain reaction (PCR) (primer sequences and conditions avail-
able upon request). PCR was carried out with a 25 μL system 
containing 100 ng genomic DNA, 1.5 mM MgCl2, 50 mMKCl, 
10 mM Tris-HCl (PH 8.3), 200 μM dNTPs, 0.5 μM of each 
primer, and 0.2 μL of Taq polyMerase (5 U/μL) (Clontech, Palo 
Alto, USA). The PCR conditions were: denaturing at 95°C for 5 
minutes followed by 35 cycles of denaturing at 94°C for 30 sec-
onds annealing at 55°C for 45 seconds and extension at 72°C 
for 1 minute; one final step at 72°C for 5 minutes.
Denaturing high-performance liquid chromatography 
PCR-DHPLC analysis was used to screen mutations from 
all coding exons and adjacent intronic splice junction regions 
of the BRCA1 and BRCA2 genes as previously described [5]. 
The DHPLC gradients and temperatures were determined by 
WAVE maker software and were properly adjusted.
Assessment of clinicopathologic features
ER, PR, histological grade (Bloom-Richardson Grading 
System) and HER2 status were collected from the pathology 
reports of the tumor samples. A triple negative breast cancer 
is characterized by the lack of ER, PR, and HER2.
RESULTS
Patient’s characteristics
A total of 79 patients were recruited in this study and were 
analyzed for both BRCA1 and BRCA2 mutation. In all the 
included patients, 32 early onset cases were diagnosed below 
35 years of age, 18 had at least one affected relative, 16 had 
bilateral breast cancer, and 3 had both bilateral breast cancer 
and affected relatives. Twenty-four were triple negative breast 
cancer with onset age below 45 years. Eight patients reported 
family history of malignancies of other organs, including the 
stomach, pancreas, gallbladder, bladder and uterus, liver and bone.
Pathogenic mutations
Six deleterious mutations in BRCA1/2 gene were found in 
the 79 patients (Table 1). Most of the BRCA1/2 mutations were 
Table 1. Disease associated BRCA1 and BRCA2
Mutation Exon AA change Age at diagnosis Ethnic group Family history Inclusion reason Previous report
BRCA1
2073delA Exon 11 36 Han Mother (OC) FH+TNBC No
2394C-T Exon 11 Q759X 44 Han TNBC Yes [11], see BIC data-
base [20]
IVS16+1G>A Exon 16, intron 16 
junction
Splice site mutation 35 Uyghur TNBC Yes, see BIC database 
[20]
BRCA2
1627A-T Exon 10 K467X 42 Han TNBC Yes [12-14], see BIC 
database [20]
6873delCTCC Exon 11 Frame shift 42 Kazakh BI-BC+FH No
9481delA Exon 24 Frame shift 35 Kazakh Early onset No
A total of 6 disease-associated mutations were detected in this study. Three mutation in BRCA1 and 3 in BRCA2. GeneBank reference sequence BRCA1 version 
#U14680.1, BRCA2 version #U43746.1.
OC=ovarian cancer; FH=family history; TNBC=triple negative breast cancer; BIC=breast cancer information core; BI-BC=bilateral breast cancer. 
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either frameshift or nonsense mutations, which resulted in 
premature truncation of the BRCA1/2 protein (Table 1). Three 
novel deleterious mutations were identified: 2073delA in BRCA1 
(Han ethnic Chinese) and BRCA2 variants 6873delCTCC and 
9481delA (both are Kazakh ethnic Chinese). Among 6 of 
BRCA-related tumors, 3 BRCA1- and 1 BRCA2-associated 
tumors were all in triple negative status.
No BRCA1/2 mutation was found in 18 patients with a family 
history of breast cancer. One pathogenic BRCA mutation (1/3, 
33.3%) was detected in 3 breast cancer patients with family 
history of ovarian cancer. Two pathogenic BRCA mutations 
(2/8, 25%) were identified in 8 breast cancer patients with family 
history of other malignancies. In 32 breast cancer patients with 
onset under 35 years old, one pathogenic BRCA (1/32, 3.1%) 
mutation was detected. One pathogenic BRCA mutation (1/16, 
6.25%) was detected in 16 patients with bilateral cancer. One 
BRCA pathogenic mutation (1/3, 33.3%) was detected in 3 
cases with bilateral breast cancer and family history of breast 
cancer or other malignancies. Four pathogenic mutations 
(16.7%) (including 3 BRCA1 mutation and 1 BRCA2 muta-
tion) were detected in 24 patients with triple negative breast 
cancer under 45 years old.
Variation of unknown significance 
In our study, three unclassified variants were detected. 
These 3 novel variants were not previously reported in the 
breast cancer information core (BIC) database (Table 2).
DISCUSSION
According to segregation analysis studies, 5% to 10% breast 
and/or ovarian cancer cases arise from an autosomal dominant 
pattern of inheritance [6,7]. Germline mutations in BRCA1 
and BRCA2 genes are responsible for the genetic predisposition 
and increased risk for breast and ovarian cancer [8,9]. The 
prevalence of BRCA mutations varies among different popula-
tions due to founder mutation effects and other environmen-
tal and geographical factors [10,11]. Genetic cancer risk assess-
ment guideline and genetic testing for inherited breast cancer 
susceptibility have become standard clinical management for 
selected patients in Western populations. But the situation 
in China is less managed, with only a very limited number 
of studies focusing on BRCA mutations among hereditary 
predisposition to breast cancer patients in China.
A few studies have reported BRCA1 and BRCA2 in high-risk 
cohorts among Chinese in Malaysia, Singapore, and Mainland 
China [12-15] with the majority of published studies in the 
Caucasian population. Ethnic Han Chinese patients were 
enrolled in most of these studies, with no study focusing on 
multiple ethnic groups in China. Moreover, up to now there 
have been no studies on the prevalence of BRCA mutations in 
triple negative breast cancer in the Chinese population.
In this study based at our hospital, 79 patients with hereditary 
predisposition to breast cancer (including patients with early 
onset breast cancer, family history of breast, ovarian cancer or 
other malignant tumors, bilateral cancer, or triple negative 
breast cancer with onset age below 45 years old) were exam-
ined for both BRCA1 and BRCA2 mutation. Six (7.6%) of the 
patients were identified to harbor a deleterious BRCA muta-
tion. Among the 79 patients, 3 (3.8%) had a BRCA1 mutation 
and 3 (3.8%) had a BRCA2 mutation. The results are consistent 
with the previous reports [3,15-17], showing BRCA2 mutation 
may not be less prevalent at least in some Asian populations. In 
contrast, in most published data from the Caucasian popula-
tion, BRCA1 germline mutation is more prevalent than BRCA2 
[18]. One pathogenic BRCA mutation (1/16, 6.25%) was detected 
among 16 bilateral cancer cases. One BRCA pathogenic muta-
tion (1/3, 33.3%) was detected in 3 bilateral breast cancer cases 
Table 2. Variants of unknown significance
Patient initials Mutation Mutation position AA change Onset age Ethnic group and FH Previous report and comment
YXQ -7 C-T 
BRCA1
5’ UTR 23 Han, early onset BC, 
  no FH
Not reported in BIC, this mutation is located 










47 Han, TNBC, no FH Not reported in BIC
Not reported in BIC, this mutation causes 













44 Han, TNBC, no FH Not reported in BIC, 3 missense mutation 
cluster in small region of exon 16 in BRCA1
GeneBank reference sequence BRCA1 version #U14680.1, BRCA2 version #U43746.1.
FH=family history; BC=breast cancer; TNBC=triple negative breast cancer; BIC=breast cancer information core. 
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with a family history of breast cancer or other malignancies. 
One pathogenic BRCA mutation (1/4, 25%) was detected in 4 
breast cancer patients with an ovarian cancer family history. 
Due to our limited sample size, more comprehensive data need 
to be collected especially for bilateral breast cancer with a family 
history and breast cancer with a family history of ovarian cancer 
in multiple ethnic regions in Xinjiang, China.
Four pathogenic mutations (16.7%) were detected in 24 
patients with triple negative breast cancer under the age of 45. 
All the 3 BRCA1 mutations are in triple negative breast cancer 
cases with higher histological grade of invasive ductal carci-
noma (average score 7.7). It is consistent with the previous 
findings in the Asian populations, including Chinese [3,15-17] 
that BRCA1 mutated tumor conferred such features: ER or PR 
negative, higher histological grade, but with less medullary 
carcinoma compared to the Western population [19]. There-
fore it is suggested that triple negative breast cancer of onset 
age below 45 may be good indicator for genetic screening in 
Chinese population. It is also supported in the recent National 
Comprehensive Cancer Network (NCCN) guidelines published 
in March 2011: ‘woman with breast cancer who was diagnosed 
up to age 45 years with or without triple negative breast cancer’ 
(http://www.jnccn.org/content/8/5/562.full).
Three BRCA1- and three BRCA2-disease-associated muta-
tions were found in our study. Among the 6 BRCA mutations, 
two BRCA1 and one BRCA2 sequence variants were found in 
BIC or published literature. BRCA1 2394 C-T (Q759X) was 
previously described in an Indian family and European popu-
lation (BIC) [20], but not identified in the Chinese population 
before. In this study this mutation was found in triple negative 
breast cancer patients with onset age 44 in ethnic Han Chinese 
group without the family history. BRCA1 IVS 16+1 G>A was 
previously reported in European and Latin American popula-
tions (BIC); in this study, it was found in an ethnic Uyghur 
triple negative breast cancer patient in China. BRCA2 1627A-
T (K467X) was previously reported in a Korean population 
and identified as recurrent mutation in the Korean population 
[21-25]. In this study it was found in a triple negative breast 
cancer patient (onset age 42) of Han Chinese ethnicity; and it 
was also the first in China. Three novel deleterious mutations 
were firstly identified in this study, which had never been 
reported in BIC or published literatures. Three of the 6 deleteri-
ous mutations in this study were found in ethnic Han Chinese 
for the first time, 1 was from Uyghur Ethnic group (never 
before reported in the Uyghur population outside China) [20, 
26-29], and 2 from Ethnic Kazak group (never before reported 
in the Kazak population outside China). It suggested that the 
BRCA mutation prevalence and spectrum in the Xinjiang 
multiple ethnic group region may arise from interaction of 
genetic background and environmental factors. 
We detected three novel mutations of unknown significance 
(Table 2). All these mutations are from 3 independent Han 
Chinese families. One early onset breast cancer case (onset 
age: 23) harbors -7 C-T BRCA1 mutation, which is located in 
5’UTR with CG-TG substitution and may influence CpG 
island function. Patient MGL harbors one BRCA1 missense 
mutation and in frame deletion in BRCA2; it is unknown 
whether these alterations influences the protein folding struc-
ture. Patient GZR harbors 3 missense mutation clustered in a 
small region of Exon 16 in BRCA1. Interestingly, D1582G 
changed aspartic acid (side-chain negative charge polarity) 
into Glycine (side chain neutral). Further functional assay 
should be done to classify the clinical significance of these 
variants. Some novel techniques could be considered for early 
breast cancer screening in China [30].
Our study only provides some preliminary information 
on the prevalence of BRCA in the Xinjiang multiple ethnic 
regions in China. Larger sample genetic testing should be 
done among the breast cancer patients with hereditary predis-
position, especially bilateral breast cancer with a family history, 
breast cancer with a family history of ovarian cancer and triple 
negative breast cancer with onset age below 45 years. We did 
find some potentially ‘hot’ BRCA mutation regions or spots in 
the Xinjiang women, but a conclusion can not be made on 
larger sample study. No founder mutation has been found in 
Xinjiang and other parts of Mainland China as yet. More data 
should be collected on BRCA distribution in Chinese breast 
cancer patients, especially in multiple ethnic regions of China. 
China is a developing country with multiple ethnic groups. 
Due to variations in the breast cancer prevalence, molecular 
subtypes and onset age among the different races and ethnici-
ties, caution must be exercised in the clinical guidelines of the 
genetic and high familial risk assessment of breast cancer in 
the NCCN data, mostly of the Western populations, in the 
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